TY - JOUR T1 - A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report JF - medRxiv DO - 10.1101/2021.03.06.21253051 SP - 2021.03.06.21253051 AU - Galit Perez AU - Tamar Banon AU - Sivan Gazit AU - Shay Ben Moshe AU - Joshua Wortsman AU - Daniel Grupel AU - Asaf Peretz AU - Amir Ben Tov AU - Gabriel Chodick AU - Miri Mizrahi-Reuveni AU - Tal Patalon Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/08/2021.03.06.21253051.abstract N2 - With more than 100 million confirmed COVID-19 cases as of March 2021, reinfection is still considered to be rare. In light of increasing reports of reinfected COVID-19 patients, the need to better understand the real risk for reinfection is critical, with potential effects on public health policies aimed at containing the spread of SARS-CoV-2. In this descriptive preliminary report, we conducted a large-scale assessment on the country level of the possible occurrence of COVID-19 reinfection within the members of a large healthcare provider in Israel. Out of 149,735 individuals with a documented positive PCR test between March 2020 and January 2021, 154 had two positive PCR tests at least 100 days apart, reflecting a reinfection proportion of 1 per 1000. Given our strict inclusion criteria, we believe these numbers represent true reinfection incidence in MHS and should be clinically regarded as such.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Maccabi health care services IRB, IsraelAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis retrospective study was conducted using data from the Maccabi Healthcare Services (MHS) central computerized database, the second largest state-mandated not-for-profit healthcare provider in Israel, containing more than 2.5 million members (approximately 25% of the population) and is a representative sample of the Israeli population. This fully computerized database captures all information on patient interaction (including demographics, visits, diagnoses, procedures and more). The data is made accessible by MHS Research and Innovation Center under the MHS institutional review board guidelines and approval. ER -